quinta-feira, 12 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 12, 2026

Is It Too Late To Consider Exxon Mobil (XOM) After Its Strong 1-Year Rally?

View original at finance.yahoo.com
Is It Too Late To Consider Exxon Mobil (XOM) After Its Strong 1-Year Rally? Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Recent headlines around Exxon Mobil have largely focused on its position in the global energy sector and investor interest in large integrated oil companies, shaping sentiment around the stock

    60% confidence

  • Exxon Mobil's projected free cash flow will grow from approximately $23.0 billion (TTM) to $48.6 billion by 2030, with intermediate annual projections between 2026 and 2035 feeding into the DCF calculation

    60% confidence

  • The P/E ratio is a useful metric for evaluating Exxon Mobil as a profitable company, with investors accepting higher or lower P/E based on earnings growth expectations and risk assessment

    60% confidence

  • Exxon Mobil has a valuation score of 4 out of 6

    60% confidence

  • Exxon Mobil is undervalued by 49.1% based on a 2-Stage Free Cash Flow to Equity DCF model, with an estimated intrinsic value of $293.99 per share versus the current share price of approximately $149.68

    60% confidence

Data points we hold from this source

Exxon Mobil Corporation · margin-49.1 percent
Exxon Mobil Corporation · cash48.6 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is It Too Late To Consider Exxon Mobil (XOM) After Its Strong 1-Year Rally? — Source | Via News | pt.VIA.NEWS